Drugs / Evobruitnib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07215806 | Aug → Nov 2022 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evobruitnib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215806 ↗ |
| Route | Oral | “Participants received Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.” NCT07215806 ↗ |